Report cover image

Colombia Gastric Cancer Drugs Market - Industry Trends and Forecast to 2029

Publisher Data Bridge Market Research
Published Feb 01, 2022
Length 118 Pages
SKU # DAABD17290027

Description

Colombia Gastric Cancer Drugs Market - Industry Trends and Forecast to 2029

Colombia gastric cancer drugs market is projected to register a substantial CAGR of 8.5% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.
Market Segmentation:
Colombia Gastric Cancer Drugs Market, By Type (Adenocarcinoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Lymphoma, and Others), Stage (Stage III, Stage II, Stage IV, Stage I, and Others), Treatment (Chemotherapy, Targeted Therapy, Immune Checkpoint Inhibitors, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Research & Academic Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) Industry Trends and Forecast to 2029

Some of the major factors contributing to the growth of the Colombia gastric cancer drugs market are:

. Rising Prevalence of gastric cancer
. Increasing technological advancements

Market Players:

The key market players for Colombia gastric cancer drugs market are listed below:
. Bayer AG
. Novartis AG
. Pfizer Inc.
. Celltrion Healthcare Co., Ltd.
. F. Hoffmann-La Roche Ltd
. Merck KGaA
. Teva Pharmaceutical Industries Ltd.
. Sanofi
. AstraZeneca
. Viatris Inc.
. Bristol-Myers Squibb Company
. Concord Biotech
. GlaxoSmithKline plc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.

Table of Contents

118 Pages
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of Colombia Gastric Cancer Drugs Market
1.4 Limitations
1.5 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Currency And Pricing
2.5 Dbmr Tripod Data Validation Model
2.6 Primary Interviews With Key Opinion Leaders
2.7 Multivariate Modelling
2.8 Type Lifeline Curve
2.9 Dbmr Market Position Grid
2.10 Vendor Share Analysis
2.11 Market End User Coverage Grid
2.12 Secondary Sources
2.13 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestel Analysis
4.2 Porters Five Forces
5 Colombia Gastric Cancer Drugs Market: Regulatory Scenario
6 Summary Write Up (Colombia)
6.1 Overview
7 Pipeline Analysis For Colombia Gastric Cancer Drugs Market
8 Market Overview
8.1 Drivers
8.1.1 Growing Gastric Cancer Burden Worldwide
8.1.2 Growing Geriatric Population
8.1.3 Increasing Initiatives By Government And Other Healthcare Organisations
8.1.4 Rising Number Of Product Approvals
8.2 Restraints
8.2.1 Adverse Effects And Risks Associated With Gastric Cancer Treatment Drugs
8.2.2 Lack Of Early Detection Of Gastric Cancer
8.3 Opportunities
8.3.1 Recent Advancements In Gastric Cancer Treatment
8.3.2 Adoption Of Automated Systems
8.3.3 Partnership And Agreement By Major Players
8.4 Challenges
8.4.1 Challenge Related To Colombian Healthcare
8.4.2 Alternative Gastric Cancer Therapies
9 Impact Of Covid-19 Pandemic On Colombia Gastric Cancer Drugs Market
9.1 Price Impact
9.2 Impact On Demand
9.3 Impact On Supply Chain
9.4 Strategic Decisions For Manufacturers
9.5 Conclusion
10 Colombia Gastric Cancer Drugs Market, By Type
10.1 Overview
10.2 Adenocarcinoma
10.3 Gastrointestinal Stromal Tumor
10.4 Carcinoid Tumor
10.5 Lymphoma
10.6 Others
11 Colombia Gastric Cancer Drugs Market, By Stages
11.1 Overview
11.2 Stage Iii
11.3 Stage Ii
11.4 Stage Iv
11.5 Stage I
11.6 Others
12 Colombia Gastric Cancer Drugs Market, By Treatment
12.1 Overview
12.2 Chemotherapy
12.2.1 Cisplatin
12.2.2 Oxaliplatin
12.2.3 Fluorouracil
12.2.4 Docetaxel
12.2.5 Capecitabine
12.2.6 Carboplatin
12.2.7 Epirubicin
12.2.8 Paclitaxel
12.2.9 Irinotecan
12.2.10 Others
12.3 Targeted Therapy
12.3.1 Monoclonal Antibody Therapy
12.3.1.1 Trastuzumab (Herceptin)
12.3.1.2 Ramucirumab
12.3.2 Multikinase Inhibitors
12.3.2.1 Sunitinib
12.3.2.2 Regorafenib
12.4 Immune Checkpoint Inhibitors
12.5 Others
13 Colombia Gastric Cancer Drugs Market, By Route Of Administration
13.1 Overview
13.2 Parenteral
13.2.1 Intravenous
13.2.2 Subcutaneous
13.2.3 Others
13.3 Oral
13.3.1 Tablet
13.3.2 Capsule
13.3.3 Others
13.4 Others
13.5 Overview
13.6 Hospitals
13.7 Speciality Clinics
13.8 Research & Academic Institutes
13.9 Others
14 Colombia Gastric Cancer Drugs Market, By Distribution Channel
14.1 Overview
14.2 Hospital Pharmacy
14.3 Retail Pharmacy
14.4 Others
15 Colombia Gastric Cancer Drugs Market: Company Landscape
15.1 Company Share Analysis: Global
16 Swot Analysis
17 Company Profile
17.1 F.Hoffman-la Roche
17.1.1 Company Snapshot
17.1.2 Revenue Analysis
17.1.3 Product Portfolio
17.1.4 Recent Development
17.1.4.1 Agreement
17.2 Merck Kgaa (A Subsidiary Of Merck & Co., Inc.)
17.2.1 Company Snapshot
17.2.2 Revenue Analysis
17.2.3 Product Portfolio
17.2.4 Recent Developments
17.2.4.1 Product Approval
17.2.4.2 Events
17.3 Teva Pharmaceutical Industries Ltd
17.3.1 Company Snapshot
17.3.2 Revenue Analysis
17.3.3 Product Portfolio
17.3.4 Recent Development
17.3.4.1 Collaboration
17.4 Sanofi
17.4.1 Company Snapshot
17.4.2 Revenue Analysis
17.4.3 Product Portfolio
17.4.4 Recent Development
17.4.4.1 Acquisition
17.5 Astrazeneca
17.5.1 Company Snapshot
17.5.2 Revenue Analysis
17.5.3 Product Portfolio
17.5.4 Recent Development
17.5.4.1 Product Approval
17.6 Bayer Ag
17.6.1 Company Snapshot
17.6.2 Revenue Analysis
17.6.3 Product Portfolio
17.6.4 Recent Development
17.6.4.1 Collaboration
17.7 Bristol-myers Squibb Company
17.7.1 Company Snapshot
17.7.2 Revenue Analysis
17.7.3 Product Portfolio
17.7.4 Recent Development
17.7.4.1 Product Approval
17.8 Celltrion Healthcare Co., Ltd.
17.8.1 Company Snapshot
17.8.2 Revenue Analysis
17.8.3 Product Portfolio
17.8.4 Recent Development
17.8.4.1 Product Approval
17.9 Concord Biotech.
17.9.1 Company Snapshot
17.9.2 Product Portfolio
17.9.3 Recent Development
17.10 Glaxosmithkline Plc.
17.10.1 Company Snapshot
17.10.2 Revenue Analysis
17.10.3 Product Portfolio
17.10.4 Recent Development
17.10.4.1 Product Approval
17.11 Novartis Ag
17.11.1 Company Snapshot
17.11.2 Revenue Analysis
17.11.3 Product Portfolio
17.11.4 Recent Development
17.11.4.1 Product Launch
17.12 Pfizer Inc.
17.12.1 Company Snapshot
17.12.2 Revenue Analysis
17.12.3 Product Portfolio
17.12.4 Recent Developments
17.12.4.1 Merger
17.12.4.2 Collaboration
17.13 Viatris Inc.
17.13.1 Company Snapshot
17.13.2 Revenue Analysis
17.13.3 Product Portfolio
17.13.4 Recent Development
18 Questionnaire
19 Related Reports
List Of Tables
Table 1 Colombia Gastric Cancer Drugs Market, By Type, 2020-2029 (Usd Million)
Table 2 Colombia Gastric Cancer Drugs Market, By Stages, 2020-2029 (Usd Million)
Table 3 Colombia Gastric Cancer Drugs Market, By Treatment, 2020-2029 (Usd Million)
Table 4 Colombia Chemotherapy In Gastric Cancer Drugs Market, By Treatment, 2020-2029 (Usd Million)
Table 5 Colombia Targeted Therapy In Gastric Cancer Drugs Market, By Treatment, 2020-2029 (Usd Million)
Table 6 Colombia Monoclonal Antibody Therapy In Gastric Cancer Drugs Market, By Treatment, 2020-2029 (Usd Million)
Table 7 Colombia Multikinase Inhibitors In Gastric Cancer Drugs Market, By Treatment, 2020-2029 (Usd Million)
Table 8 Colombia Gastric Cancer Drugs Market, By Route Of Administration, 2020-2029 (Usd Million)
Table 9 Colombia Parentral In Gastric Cancer Drugs Market, By Route Of Administration, 2020-2029 (Usd Million)
Table 10 Colombia Oral In Gastric Cancer Drugs Market, By Route Of Administration, 2020-2029 (Usd Million)
Table 11 Colombia Gastric Cancer Drugs Market, By End Users, 2020-2029 (Usd Million)
Table 12 Colombia Gastric Cancer Drugs Market, By Distribution Channel, 2020-2029 (Usd Million)
List Of Figures
Figure 1 Colombia Gastric Cancer Drugs Market: Segmentation
Figure 2 Colombia Gastric Cancer Drugs Market: Data Triangulation
Figure 3 Colombia Gastric Cancer Drugs Market: Droc Analysis
Figure 4 Colombia Gastric Cancer Drugs Market: Global Vs Regional Market Analysis
Figure 5 Colombia Gastric Cancer Drugs Market: Company Research Analysis
Figure 6 Colombia Gastric Cancer Drugs Market: Interview Demographics
Figure 7 Colombia Gastric Cancer Drugs Market: Multivariate Modelling
Figure 8 Colombia Gastric Cancer Drugs Market: Dbmr Market Position Grid
Figure 9 Colombia Gastric Cancer Drugs Market: Vendor Share Analysis
Figure 10 Colombia Gastric Cancer Drugs Market: End User Overage Grid
Figure 11 Colombia Gastric Cancer Drugs Market: Segmentation
Figure 12 Increasing In Incidence Of Gastrointestinal Tumors, Lymphoma And Adenocarcinoma And High Prevalence Of Obesity Are Expected To Drive The Colombia Gastric Cancer Drugs Market In The Forecast Period Of 2022 To 2029
Figure 13 Type Segment Is Expected To Account For The Largest Share Of The Colombia Gastric Cancer Drugs Market In 2022 & 2029
Figure 14 Regulatory Process Of Drugs And Biologics Approval In Colombia
Figure 15 Drivers, Restraints, Opportunities, And Challenges Of Colombia Gastric Cancer Drugs Market
Figure 16 Colombia Gastric Cancer Drugs Market: By Type, 2021
Figure 17 Colombia Gastric Cancer Drugs Market: By Type, 2020-2029 (Usd Million)
Figure 18 Colombia Gastric Cancer Drugs Market: By Type, Cagr (2022-2029)
Figure 19 Colombia Gastric Cancer Drugs Market: By Type, Lifeline Curve
Figure 20 Colombia Gastric Cancer Drugs Market: By Stages, 2021
Figure 21 Colombia Gastric Cancer Drugs Market: By Stages, 2020-2029 (Usd Million)
Figure 22 Colombia Gastric Cancer Drugs Market: By Stages, Cagr (2022-2029)
Figure 23 Colombia Gastric Cancer Drugs Market: By Stages, Lifeline Curve
Figure 24 Colombia Gastric Cancer Drugs Market: By Treatment, 2021
Figure 25 Colombia Gastric Cancer Drugs Market: By Treatment, 2020-2029 (Usd Million)
Figure 26 Colombia Gastric Cancer Drugs Market: By Treatment, Cagr (2022-2029)
Figure 27 Colombia Gastric Cancer Drugs Market: By Treatment, Lifeline Curve
Figure 28 Colombia Gastric Cancer Drugs Market: By Route Of Aministration, 2021
Figure 29 Colombia Gastric Cancer Drugs Market: By Route Of Administration, 2020-2029 (Usd Million)
Figure 30 Colombia Gastric Cancer Drugs Market: By Route Of Aministration, Cagr (2022-2029)
Figure 31 Colombia Gastric Cancer Drugs Market: By Route Of Aministration, Lifeline Curve
Figure 32 Colombia Gastric Cancer Drugs Market: By End Users, 2021
Figure 33 Colombia Gastric Cancer Drugs Market: By End Users, 2020-2029 (Usd Million)
Figure 34 Colombia Gastric Cancer Drugs Market: By End Users, Cagr (2022-2029)
Figure 35 Colombia Gastric Cancer Drugs Market: By End Users, Lifeline Curve
Figure 36 Colombia Gastric Cancer Drugs Market: By Distribution Channel, 2021
Figure 37 Colombia Gastric Cancer Drugs Market: By Distribution Channel, 2020-2029 (Usd Million)
Figure 38 Colombia Gastric Cancer Drugs Market: By Distribution Channel, Cagr (2022-2029)
Figure 39 Colombia Gastric Cancer Drugs Market: By Distribution Channel, Lifeline Curve
Figure 40 Colombia Gastric Cancer Drugs Market: Company Share 2021 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us